Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Michael K. Samson"'
Publikováno v:
Investigational New Drugs. 11:223-226
Amonafide (AMF), NSC 308847 is an investigational anticancer drug acting as a DNA intercalating agent. This paper presents results of a phase II clinical study of AMF in disseminated malignant melanoma. Twenty patients, eleven males and nine females,
Autor:
Michael K. Samson, Kenneth J. Kopecky, D. D. Von Hoff, Raymond A. Kempf, Franco M. Muggia, William S. Fletcher, Julie A. Kish
Publikováno v:
Investigational New Drugs. 9:105-108
Twenty-seven evaluable patients with advanced malignant melanoma received fludarabine phosphate in a daily x 5 injection. Initial dosing was based on the presence of previous radiation therapy. There was no response seen in these patients despite app
Publikováno v:
Chest. 99:89-91
We evaluated the feasibility of utilizing physician assistants as providers of primary care in a medical ICU. After a three-month period of rigorous training, two PAs were assigned to the ICU. Their performance as well as the operation of the ICU ove
Autor:
Robert P. Whitehead, Evan M. Hersh, Kenneth J. Kopecky, Rinehart Jj, Natale Rb, Michael K. Samson, Lynn G. Feun, Costanzi Jj
Publikováno v:
Journal of the National Cancer Institute. 83(17)
Autor:
Michael K. Samson, Ronald L. Stephens, Brent A. Blumenstein, Antoinette J. Wozniak, N T Shah, Ronald B. Natale, B A Bouroncle, E D Crawford, S J Altman, C D Ford
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 9(1)
This is a Southwest Oncology Group (SWOG) prospective randomized trial of cisplatin, vinblastine, and bleomycin (PVB) versus vinblastine, cisplatin, and etoposide (VP-16) (VPV) in the treatment of advanced germ cell tumors of the testis. The study ob
Publikováno v:
AMERICAN JOURNAL OF CLINICAL ONCOLOGY. 5:631-634
Thirty-four assessable patients with advanced squamous cell and adenocarcinoma of the lung were treated with weekly MGBG in a phase II trial. Only one partial response, in adenocarcinoma, was observed. Myelosuppression was mild to moderate. Major tox
Autor:
Bruce McDonald, Vainutis K. Vaitkevicius, Lawrence Leichman, Michael K. Samson, Aydin Dindogru
Publikováno v:
Cancer. 53:18-22
Cis-diamminedichloroplatinum (DDP) was administered at 100 mg/m2 intravenously bolus with every 3-week schedule in patients with measurable and nonmeasurable incurable gastric cancer. Twenty patients were treated, 12 with measurable and 8 with nonmea
Publikováno v:
American Journal of Clinical Oncology. 8:167-171
Thirty-seven fully assessable patients with metastatic malignant melanoma were administered DTIC, actinomycin-D, and dibromodulcitol (DBD) on a q 3- to 4-week schedule. Doses of actinomycin-D and DTIC were 1.25 mg/m2 and 750 mg/m2, respectively, on d
Autor:
Laurence H. Baker, Fraile Rj, Robert W. Brownlee, Ahmad M. Samhouri, Michael K. Samson, Talley Rw
Publikováno v:
European Journal of Cancer (1965). 17:337-343
A phase II evaluation of chlorozoticin (CZT), a water soluble nitrosourea, was undertaken to determine its effectiveness and toxicity in a variety of human metastatic neoplasms. The dosage regimen chosen was either 90 or 120 mg/m 2 given by i.v. bolu
Autor:
W. G. Tucker, Saul E. Rivkin, Edward Weber, Michael K. Samson, Frank E. Smith, Joseph M. Quagliana, Jeffrey A. Gottlieb, Arthur Haut, Bill L. Tranum, Michael T. Shaw
Publikováno v:
Cancer. 35:1148-1153
In March of 1972, the Southwest Oncology Group initiated a Phase II study, No. 7200, utilizing methyl-CCNU in the treatment of patients with solid tumors and lymphomas. Initially, they received 200 mg/m2 orally as a single dose every 6 weeks. The dos